Diagnosis and treatment of hepatocellular carcinoma

被引：0

作者：

Bathon, Melanie ^{[1
]}

Saborowski, Anna ^{[1
]}

Vogel, Arndt ^{[1
]}

机构：

[1] Hannover Med Sch, Klin Gastroenterol Hepatol Infektiol & Endokrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany

来源：

GASTROENTEROLOGIE | 2024年 / 19卷 / 03期

关键词：

Liver cirrhosis; Ablation techniques; Therapeutic chemoembolization; Immunotherapy; Tyrosine kinase inhibitors; ATEZOLIZUMAB PLUS BEVACIZUMAB; LIVER-TRANSPLANTATION; SORAFENIB; RESECTION; OUTCOMES; THERAPY; CANCER; TRIAL;

D O I：

10.1007/s11377-024-00795-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Due to the increase in steatotic liver diseases, the incidence is currently rising, particularly in Western countries. Depending on the patient's performance status, liver function and tumor stage, a wide range of therapeutic options are now available. These range from surgical procedures, such as liver transplantation and resection, to interventional therapies, such as ablation or transarterial chemoembolization, to systemic therapies in advanced stages. The recent approval of immunotherapies has significantly improved the landscape of systemic treatment options. Due to the diversity of therapeutic approaches, multidisciplinary care in experienced centers with a focus on liver tumors is crucial.

引用

页码：247 / 257

页数：11

共 30 条

[1] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].

Abou-Alfa, Ghassan K. ;

Chan, Stephen Lam ;

Kudo, Masatoshi ;

Lau, George ;

Kelley, Robin Kate ;

Furuse, Junji ;

Sukeepaisarnjaroen, Wattana ;

Kang, Yoon-Koo ;

Dao, Tu V. ;

De Toni, Enrico N. ;

Rimassa, Lorenza ;

Breder, Valeriy Vladimirovich ;

Vasilyev, Alexander ;

Heurgue, Alexandra ;

Tam, Vincent ;

Mody, Kabir ;

Thungappa, Satheesh Chiradoni ;

He, Philip ;

Negro, Alejandra ;

Sangro, Bruno .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[2] Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone [J].

Brown, Karen T. ;

Do, Richard K. ;

Gonen, Mithat ;

Covey, Anne M. ;

Getrajdman, George I. ;

Sofocleous, Constantinos T. ;

Jarnagin, William R. ;

D'Angelica, Michael I. ;

Allen, Peter J. ;

Erinjeri, Joseph P. ;

Brody, Lynn A. ;

O'Neill, Gerald P. ;

Johnson, Kristian N. ;

Garcia, Alessandra R. ;

Beattie, Christopher ;

Zhao, Binsheng ;

Solomon, Stephen B. ;

Schwartz, Lawrence H. ;

DeMatteo, Ronald ;

Abou-Alfa, Ghassan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) :2046-+

[3] SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma [J].

Chow, Pierce K. H. ;

Gandhi, Mihir ;

Tan, Say-Beng ;

Khin, Maung Win ;

Khasbazar, Ariunaa ;

Ong, Janus ;

Choo, Su Pin ;

Cheow, Peng Chung ;

Chotipanich, Chanisa ;

Lim, Kieron ;

Lesmana, Laurentius A. ;

Manuaba, Tjakra W. ;

Yoong, Boon Koon ;

Raj, Aloysius ;

Law, Chiong Soon ;

Cua, Ian H. Y. ;

Lobo, Rolley R. ;

Teh, Catherine S. C. ;

Kim, Yun Hwan ;

Jong, Yun Won ;

Han, Ho-Seong ;

Bae, Si-Hyun ;

Yoon, Hyun-Ki ;

Lee, Rheun-Chuan ;

Hung, Chien-Fu ;

Peng, Cheng-Yuan ;

Liang, Po-Chin ;

Bartlett, Adam ;

Kok, Kenneth Y. Y. ;

Thng, Choon-Hua ;

Low, Albert Su-Chong ;

Goh, Anthony S. W. ;

Tay, Kiang Hiong ;

Lo, Richard H. G. ;

Goh, Brian K. P. ;

Ng, David C. E. ;

Lekurwale, Ganesh ;

Liew, Wei Ming ;

Gebski, Val ;

Mak, Kenneth S. W. ;

Soo, Khee Chee .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) :1913-+

[4] Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma [J].

Citterio, Davide ;

Facciorusso, Antonio ;

Sposito, Carlo ;

Rota, Roberta ;

Bhoori, Sherrie ;

Mazzaferro, Vincenzo .

JAMA SURGERY, 2016, 151 (09) :846-853

[5] Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West [J].

Dang, Hansen ;

Yeo, Yee Hui ;

Yasuda, Satoshi ;

Huang, Chung-Feng ;

Iio, Etsuko ;

Landis, Charles ;

Jun, Dae Won ;

Enomoto, Masaru ;

Ogawa, Eiichi ;

Tsai, Pei-Chien ;

Le, An ;

Liu, Matthew ;

Maeda, Mayumi ;

Nguyen, Brian ;

Ramrakhiani, Nathan ;

Henry, Linda ;

Cheung, Ramsey ;

Tamori, Akihiro ;

Kumada, Takashi ;

Tanaka, Yasuhito ;

Yu, Ming-Lung ;

Toyoda, Hidenori ;

Nguyen, Mindie H. .

HEPATOLOGY, 2020, 71 (06) :1910-1922

[6]

esmo, About Us

[7] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). [J].

Finn, Richard S. ;

Qin Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Lim, Ho Yeong ;

Kudo, Masatoshi ;

Breder, Valeriy Vladimirovich ;

Merle, Philippe ;

Kaseb, Ahmed Omar ;

Li Daneng ;

Verret, Wendy ;

Shao Hui ;

Liu Juan ;

Li Lindong ;

Zhu, Andrew X. ;

Chen, Ann-Lii .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[8] Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma [J].

Forner, Alejandro ;

Vilana, Ramon ;

Ayuso, Carmen ;

Bianchi, Lluis ;

Sole, Manel ;

Ayuso, Juan Ramon ;

Boix, Loreto ;

Sala, Margarita ;

Varela, Maria ;

Llovet, Josep M. ;

Bru, Concepcio ;

Bruix, Jordi .

HEPATOLOGY, 2008, 47 (01) :97-104

[9] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial [J].

Galle, Peter R. ;

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Zhu, Andrew X. ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed ;

Li, Daneng ;

Mulla, Sohail ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Ding, Beiying ;

Liu, Juan ;

Huang, Chen ;

Lim, Ho Yeong ;

Cheng, Ann-Lii ;

Ducreux, Michel .

LANCET ONCOLOGY, 2021, 22 (07) :991-1001

[10] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation [J].

Hack, Stephen P. ;

Spahn, Jessica ;

Chen, Minshan ;

Cheng, Ann-Lii ;

Kaseb, Ahmed ;

Kudo, Masatoshi ;

Lee, Han Chu ;

Yopp, Adam ;

Chow, Pierce ;

Qin, Shukui .

FUTURE ONCOLOGY, 2020, 16 (15) :975-989

← 1 2 3 →